Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits

British Journal of Nutrition

Volumn 112, Issue 8, 2014, Pages 1315-1322

  Egert, Sarah ^a   Baxheinrich, Andrea ^b   Lee Barkey, Young Hee ^c   Tschoepe, Diethelm ^c   Wahrburg, Ursel ^b   Stratmann, Bernd ^c  

^a UNIVERSITY OF BONN   (Germany)

^b MÜNSTER UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Blood pressure; Endothelial function; Energy restriction; Inflammation; Linolenic acid

Indexed keywords

C REACTIVE PROTEIN; CHITINASE 3 LIKE PROTEIN 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLYCOPROTEIN GP 39; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LINOLENIC ACID; MEMBRANE PROTEIN; N(G),N(G) DIMETHYLARGININE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADIPOCYTOKINE; ARGININE; AUTACOID; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; ICAM1 PROTEIN, HUMAN; LECTIN; N,N-DIMETHYLARGININE; RAPESEED OIL; SELE PROTEIN, HUMAN; VEGETABLE OIL;

ADULT; ARTERIAL PRESSURE; ARTICLE; BIOLOGICAL FUNCTIONS; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; CALORIC INTAKE; CALORIC RESTRICTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL FUNCTION; FAT MASS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITIONAL ASSESSMENT; OBESITY; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; DIET THERAPY; DOWN REGULATION; IMMUNOLOGY; LOW CALORY DIET; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULITIS;

ADIPOKINES; ADULT; ALPHA-LINOLENIC ACID; ARGININE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIET, REDUCING; DOWN-REGULATION; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LECTINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PLANT OILS; VASCULITIS; WEIGHT LOSS;

EID: 84922019312     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114514002001     Document Type: Article

References (50)

1. Alberti KG, Eckel RH, Grundy SM, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645.
2. Wilson PW, D'Agostino RB, Parise H, et al. (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066-3072.
3. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59, 635-643.
4. Di Pino A, Alagona C, Piro S, et al. (2012) Separate impact of metabolic syndrome and altered glucose tolerance on early markers of vascular injuries. Atherosclerosis 223, 458-462.
5. Niccoli G, Giubilato S, Di Vito L, et al. (2013) Severity of coronary atherosclerosis in patients with a first acute coronary event: a diabetes paradox. Eur Heart J 34, 729-741.
6. Suzuki T, Hirata K, Elkind MS, et al. (2008) Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 156, 405-410.
7. Hope SA & Meredith IT (2003) Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. Intern Med J 33, 380-386.
8. Hope SA & Meredith IT (2003) Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern Med J 33, 450-462.
9. Jacobs M, van Greevenbroek MM, van der Kallen CJ, et al. (2011) The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Invest 41, 167-175.
10. Palomo IG, Jaramillo JC, Alarcon ML, et al. (2009) Increased concentrations of soluble vascular cell adhesion molecule-1 and soluble CD40L in subjects with metabolic syndrome. Mol Med Rep 2, 481-485.
11. Alexopoulos N, Katritsis D & Raggi P (2014) Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis 233, 104-112.
12. Choi J, Joseph L & Pilote L (2013) Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14, 232-244.
13. Khosravi R, Ka K, Huang T, et al. (2013) Tumor necrosis factor-α and interleukin-6: potential interorgan inflammatory mediators contributing to destructive periodontal disease in obesity or metabolic syndrome. Mediators Inflamm, article ID 728987, 1-6.
14. Rathcke CN & Vestergaard H (2009) YKL-40 - an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8, 61.
15. Kastrup J, Johansen JS, Winkel P, et al. (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30, 1066-1072.
16. Harutyunyan M, Gotze JP, Winkel P, et al. (2013) Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 218, 945-951.
17. Nielsen AR, Erikstrup C, Johansen JS, et al. (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57, 3078-3082.
18. Hempen M, Kopp HP, Elhenicky M, et al. (2009) YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 19, 1557-1563.
19. Rathcke CN, Johansen JS & Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55, 53-59.
20. Saravanan P, Davidson NC, Schmidt EB, et al. (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376, 540-550.
21. He K (2009) Fish, long-chain omega-3 polyunsaturated fatty acids and prevention of cardiovascular disease - eat fish or take fish oil supplement? Prog Cardiovasc Dis 52, 95-114.
22. Wang C, Harris WS, Chung M, et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 5-17.
23. Egert S & Stehle P (2011) Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 14, 121-131.
24. Jacobs B, Angelis-Schierbaum G, Egert S, et al. (2004) Individual serum triglyceride responses to high-fat and low-fat diets differ in men with modest and severe hypertriglyceridemia. J Nutr 134, 1400-1405.
25. de Roos B, Mavrommatis Y & Brouwer IA (2009) Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 158, 413-428.
26. Stirban A, Nandrean S, Gotting C, et al. (2010) Effects of n-3 fatty acids on macro-and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91, 808-813.
27. Egert S, Kannenberg F, Somoza V, et al. (2009) Dietary α-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 139, 861-868.
28. Stark AH, Crawford MA & Reifen R (2008) Update on α-linolenic acid. Nutr Rev 66, 326-332.
29. Poudyal H, Panchal SK, Diwan V, et al. (2011) Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res 50, 372-387.
30. Rodriguez-Leyva D, Dupasquier CM, McCullough R, et al. (2010) The cardiovascular effects of flaxseed and its omega-3 fatty acid, α-linolenic acid. Can J Cardiol 26, 489-496.
31. Baxheinrich A, Stratmann B, Lee-Barkey YH, et al. (2012) Effects of a rapeseed oil-enriched hypoenergetic diet with a high content of α-linolenic acid on body weight and cardiovascular risk profile in patients with the metabolic syndrome. Br J Nutr 108, 682-691.
32. Alberti KG, Zimmet P & Shaw J (2005) The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062.
33. Wycherley TP, Brinkworth GD, Keogh JB, et al. (2010) Longterm effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. J Intern Med 267, 452-461.
34. Clifton PM, Keogh JB, Foster PR, et al. (2005) Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets. Int J Obes (Lond) 29, 1445-1451.
35. Keogh JB, Brinkworth GD, Noakes M, et al. (2008) Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. Am J Clin Nutr 87, 567-576.
36. Neter JE, Stam BE, Kok FJ, et al. (2003) Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42, 878-884.
37. Frigolet ME, Torres N & Tovar AR (2013) The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 24, 2003-2015.
38. Masuo K, Rakugi H, Ogihara T, et al. (2010) Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 6, 58-67.
39. Soare A, Weiss EP & Pozzilli P (2014) Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk. Diabetes Metab Res Rev 30, Suppl. 1, 41-47.
40. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703-713.
41. Paschos GK, Magkos F, Panagiotakos DB, et al. (2007) Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients. Eur J Clin Nutr 61, 1201-1206.
42. Bemelmans WJ, Broer J, Feskens EJ, et al. (2002) Effect of an increased intake of α-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. Am J Clin Nutr 75, 221-227.
43. Finnegan YE, Minihane AM, Leigh-Firbank EC, et al. (2003) Plant-and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am J Clin Nutr 77, 783-795.
44. Singer P, Berger I, Wirth M, et al. (1986) Slow desaturation and elongation of linoleic and α-linolenic acids as a rationale of eicosapentaenoic acid-rich diet to lower blood pressure and serum lipids in normal, hypertensive and hyperlipemic subjects. Prostaglandins Leukot Med 24, 173-193.
45. Cabo J, Alonso R & Mata P (2012) Omega-3 fatty acids and blood pressure. Br J Nutr 107, Suppl. 2, S195-S200.
46. Goyens PL, Spilker ME, Zock PL, et al. (2005) Compartmental modeling to quantify α-linolenic acid conversion after longer term intake of multiple tracer boluses. J Lipid Res 46, 1474-1483.
47. Goyens PL, Spilker ME, Zock PL, et al. (2006) Conversion of α-linolenic acid in humans is influenced by the absolute amounts of α-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 84, 44-53.
48. Ziccardi P, Nappo F, Giugliano G, et al. (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804-809.
49. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351, 88-92.
50. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. (2011) Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab 96, 200-209.